Supernus Pharmaceuticals, Inc. (SUPN)

NASDAQ: SUPN · IEX Real-Time Price · USD
36.39
-0.01 (-0.03%)
Mar 28, 2023, 4:00 PM EDT - Market closed
-0.03%
Market Cap 1.98B
Revenue (ttm) 667.24M
Net Income (ttm) 60.71M
Shares Out 54.38M
EPS (ttm) 1.04
PE Ratio 34.99
Forward PE 20.16
Dividend n/a
Ex-Dividend Date n/a
Volume 251,004
Open 36.20
Previous Close 36.40
Day's Range 34.37 - 36.59
52-Week Range 24.95 - 42.09
Beta 1.01
Analysts Buy
Price Target 43.61 (+19.84%)
Earnings Date May 8, 2023

About SUPN

Supernus Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system (CNS) diseases in the United States. Its commercial products are Trokendi XR, an extended release topiramate product indicated for the treatment of epilepsy, as well as for the prophylaxis of migraine headache; and Oxtellar XR, an extended release oxcarbazepine for the monotherapy treatment of partial onset epilepsy seizures in adults and children between 6 to 17 years of age. The ... [Read more]

Sector Healthcare
IPO Date May 1, 2012
Employees 575
Stock Exchange NASDAQ
Ticker Symbol SUPN
Full Company Profile

Financial Performance

In 2022, SUPN's revenue was $667.24 million, an increase of 15.09% compared to the previous year's $579.78 million. Earnings were $60.71 million, an increase of 13.64%.

Financial Statements

Analyst Forecast

According to 10 analysts, the average rating for SUPN stock is "Buy." The 12-month stock price forecast is $43.61, which is an increase of 19.84% from the latest price.

Price Target
$43.61
(19.84% upside)
Analyst Consensus: Buy
Stock Forecasts

News

Supernus to Participate in Two Upcoming Investor Conferences

ROCKVILLE, Md., March 08, 2023 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a biopharmaceutical company focused on developing and commercializing products for the treatment of ce...

2 weeks ago - GlobeNewsWire

Supernus to Present at the Cowen 43rd Annual Health Care Conference

ROCKVILLE, Md., March 01, 2023 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a biopharmaceutical company focused on developing and commercializing products for the treatment of ce...

3 weeks ago - GlobeNewsWire

Supernus Pharmaceuticals (SUPN) Q4 Earnings and Revenues Lag Estimates

Supernus (SUPN) delivered earnings and revenue surprises of -41.10% and 8.15%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?

1 month ago - Zacks Investment Research

Supernus Announces Fourth Quarter and Full Year 2022 Financial Results

1 Includes net product sales reported by Adamas Pharmaceuticals prior to the acquisition of Adamas by Supernus Pharmaceuticals in November 2021.

1 month ago - GlobeNewsWire

Supernus Pharmaceuticals (SUPN) Earnings Expected to Grow: Should You Buy?

Supernus (SUPN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

1 month ago - Zacks Investment Research

Supernus Enters Into $150 Million Credit Facility

ROCKVILLE, Md., Feb. 14, 2023 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a biopharmaceutical company focused on developing and commercializing products for the treatment of cen...

1 month ago - GlobeNewsWire

Supernus Pharmaceuticals to Announce Fourth Quarter and Full Year 2022 Financial Results and Host Conference Call on February 28, 2023

ROCKVILLE, Md., Feb. 09, 2023 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a biopharmaceutical company focused on developing and commercializing products for the treatment of cen...

1 month ago - GlobeNewsWire

Supernus to Present at the Piper Sandler 34th Annual Healthcare Conference

ROCKVILLE, Md., Nov. 22, 2022 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a biopharmaceutical company focused on developing and commercializing products for the treatment of cen...

4 months ago - GlobeNewsWire

Supernus Pharmaceuticals (SUPN) Misses Q3 Earnings Estimates

Supernus (SUPN) delivered earnings and revenue surprises of -90.63% and 2.39%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

5 months ago - Zacks Investment Research

Supernus to Present at Two November Healthcare Conferences

ROCKVILLE, Md., Nov. 08, 2022 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a biopharmaceutical company focused on developing and commercializing products for the treatment of cen...

5 months ago - GlobeNewsWire

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Supernus Pharmaceuticals, Inc. - SUPN

NEW YORK , Nov. 4, 2022 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of  Supernus Pharmaceuticals, Inc. (""Supernus" or the "Company") (NASDAQ: SUPN).  Such investors a...

5 months ago - PRNewsWire

Supernus Pharmaceuticals to Announce Third Quarter 2022 Financial Results and Host Conference Call on November 8, 2022

ROCKVILLE, Md., Oct. 25, 2022 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a biopharmaceutical company focused on developing and commercializing products for the treatment of cen...

5 months ago - GlobeNewsWire

Supernus Provides Regulatory Update on SPN-830

ROCKVILLE, Md., Oct. 10, 2022 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a pharmaceutical company focused on developing and commercializing products for the treatment of centra...

6 months ago - GlobeNewsWire

Supernus to Present at the 2022 Wells Fargo Healthcare Conference

ROCKVILLE, Md., Aug. 31, 2022 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a biopharmaceutical company focused on developing and commercializing products for the treatment of cen...

7 months ago - GlobeNewsWire

Best Momentum Stocks to Buy for August 8th

CLH, NETI and SUPN made it to the Zacks Rank #1 (Strong Buy) momentum stocks list on August 8, 2022.

Other symbols: CLHNETI
8 months ago - Zacks Investment Research

Supernus Pharmaceuticals (SUPN) Q2 Earnings Lag Estimates

Supernus (SUPN) delivered earnings and revenue surprises of -53.33% and 2.23%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

8 months ago - Zacks Investment Research

Supernus Announces Second Quarter 2022 Financial Results

ROCKVILLE, Md., Aug. 04, 2022 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a biopharmaceutical company focused on developing and commercializing products for the treatment of cen...

8 months ago - GlobeNewsWire

Supernus Pharmaceuticals to Announce Second Quarter 2022 Financial Results and Host Conference Call on August 4, 2022

ROCKVILLE, Md., July 25, 2022 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a biopharmaceutical company focused on developing and commercializing products for the treatment of cen...

8 months ago - GlobeNewsWire

Supernus to Participate in the Jefferies Healthcare Conference

ROCKVILLE, Md., June 02, 2022 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a biopharmaceutical company focused on developing and commercializing products for the treatment of cen...

10 months ago - GlobeNewsWire

Supernus Announces First Quarter 2022 Financial Results

ROCKVILLE, Md., May 09, 2022 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a biopharmaceutical company focused on developing and commercializing products for the treatment of cent...

11 months ago - GlobeNewsWire

Supernus Pharmaceuticals to Announce First Quarter 2022 Financial Results and Host Conference Call on May 9, 2022

ROCKVILLE, Md., May 02, 2022 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a biopharmaceutical company focused on developing and commercializing products for the treatment of cent...

11 months ago - GlobeNewsWire

FDA Approves Expanded Use Of Supernus' Viloxazine In Adult ADHD Patients

The FDA approved an expanded indication for Supernus Pharmaceuticals Inc's (NASDAQ: SUPN) Qelbree (viloxazine extended-release capsules) for attention deficit hyperactivity disorder (ADHD) in adult pa...

11 months ago - Benzinga

Supernus Announces FDA Approval of Qelbree® for the Treatment of ADHD in Adults

First novel, nonstimulant option for adults with ADHD in 20 years ADHD affects an estimated 10 million adults in the U.S. ROCKVILLE, Md. , May 2, 2022 /PRNewswire/ -- Supernus Pharmaceuticals, Inc. (N...

11 months ago - PRNewsWire

Supernus Reports Final Audited Fourth Quarter and Full Year 2021 Financial Results

ROCKVILLE, Md., April 13, 2022 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a biopharmaceutical company focused on developing and commercializing products for the treatment of ce...

1 year ago - GlobeNewsWire

Supernus Provides Update on Filing of Annual Report and Reiterates Full Year 2022 Financial Guidance

ROCKVILLE, Md., April 04, 2022 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a biopharmaceutical company focused on developing and commercializing products for the treatment of ce...

1 year ago - GlobeNewsWire